TL;DR: The Centers for Medicare & Medicaid Services modified NCD 158 governing IVIg coverage for autoimmune mucocutaneous blistering diseases, with a policy update effective March 7, 2026. Here's what billing teams need to do.
CMS — the Centers for Medicare & Medicaid Services — updated NCD 158, the National Coverage Determination governing Medicare reimbursement for intravenous immune globulin (IVIg) used to treat autoimmune mucocutaneous blistering diseases including Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita. The policy does not list specific CPT or HCPCS codes — a point that matters for your charge capture workflow and one we'll address directly. What it does contain is a structured, condition-by-condition framework for medical necessity that your billing team needs to have memorized before submitting any IVIg claims under this NCD.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases |
| Policy Code | NCD 158 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | High |
| Specialties Affected | Dermatology, Rheumatology, Immunology, Infusion Therapy, Hospital Outpatient, Hematology |
| Key Action | Audit all active IVIg orders for the five covered diagnoses against the three patient subpopulation criteria and confirm "short-term therapy" documentation is in the record before March 7, 2026 |
CMS IVIg Coverage Criteria and Medical Necessity Requirements for Mucocutaneous Blistering Diseases 2026
This is where most IVIg claim denials originate, and NCD 158 is more specific than many billing teams realize. Coverage is not automatic just because a patient carries one of the five qualifying diagnoses. There are two hard gates you have to clear.
Gate one: biopsy confirmation. The disease must be biopsy-proven. Not clinically suspected, not pending pathology — proven. If that biopsy result isn't documented in the record before you bill, you're looking at a medical necessity denial. Pull the path report before the claim goes out.
Gate two: patient subpopulation eligibility. CMS requires the patient to fall into at least one of three categories:
| # | Covered Indication |
|---|---|
| 1 | The patient has failed conventional therapy. |
| 2 | Conventional therapy is otherwise contraindicated for this patient. |
| 3 | The patient has rapidly progressive disease where a clinical response using conventional agents cannot be achieved quickly enough. In this scenario, IVIg is given alongside conventional treatment — not as a replacement — and only until conventional therapy takes effect. |
Here's the part that will trip up your billing team if you're not paying attention: CMS explicitly delegates definition authority to Medicare Administrative Contractors (MACs). Your MAC decides what constitutes "failure of conventional therapy." Your MAC decides what constitutes a contraindication to conventional therapy. Your MAC decides what counts as "short-term therapy."
That's not ambiguous language buried in a footnote — it's the actual coverage policy framework. Pull your MAC's Local Coverage Determination (LCD) for IVIg right now and cross-reference it with NCD 158. If your MAC has published specific criteria, those criteria govern your claims. If they haven't, document your clinical rationale thoroughly and talk to your compliance officer before the March 7, 2026 effective date.
The maintenance therapy prohibition is categorical. IVIg under NCD 158 is short-term only. Not long-term, not maintenance, not indefinite. If a patient's chart shows ongoing IVIg infusions without a documented endpoint or re-evaluation tied to one of the three eligibility criteria, that's a vulnerability. Fix it before March 7, 2026.
CMS IVIg Exclusions and Non-Covered Indications Under NCD 158
NCD 158 is a covered-with-conditions policy, not an exclusion-heavy one — but the boundaries are clear. IVIg for mucocutaneous blistering diseases is not covered when:
| # | Excluded Procedure |
|---|---|
| 1 | The patient does not have biopsy-proven disease in one of the five listed conditions |
| 2 | The patient has not failed conventional therapy, lacks a contraindication to it, and does not have rapidly progressive disease |
| 3 | IVIg is being used as maintenance therapy rather than short-term therapy |
Any use of IVIg for mucocutaneous blistering diseases outside those three subpopulation criteria is non-covered under this NCD. There is no coverage pathway for patients who simply prefer IVIg over steroids or immunosuppressants absent one of those three clinical justifications.
Coverage Indications at a Glance
| Indication | Coverage Status | Key Requirement | Notes |
|---|---|---|---|
| Pemphigus Vulgaris | Covered | Biopsy-proven; meets one of three patient subpopulation criteria | Short-term only; MAC defines "failure" and "short-term" |
| Pemphigus Foliaceus | Covered | Biopsy-proven; meets one of three patient subpopulation criteria | Short-term only; MAC defines "failure" and "short-term" |
| Bullous Pemphigoid | Covered | Biopsy-proven; meets one of three patient subpopulation criteria | Short-term only; MAC defines "failure" and "short-term" |
| Mucous Membrane Pemphigoid (Cicatricial Pemphigoid) | Covered | Biopsy-proven; meets one of three patient subpopulation criteria | Short-term only; MAC defines "failure" and "short-term" |
| Epidermolysis Bullosa Acquisita | Covered | Biopsy-proven; meets one of three patient subpopulation criteria | Short-term only; MAC defines "failure" and "short-term" |
| IVIg as maintenance therapy for any of the above | Not Covered | N/A | Explicitly excluded regardless of diagnosis |
| Rapidly progressive disease — IVIg as sole therapy | Not Covered | N/A | Must be given concurrently with conventional treatment |
| Any mucocutaneous blistering disease without biopsy confirmation | Not Covered | N/A | Clinical diagnosis alone is insufficient |
CMS IVIg Billing Guidelines and Action Items for NCD 158 in 2026
| # | Action Item |
|---|---|
| 1 | Pull your MAC's LCD for IVIg before March 7, 2026. NCD 158 explicitly grants MACs discretion to define failure of conventional therapy, contraindications, and short-term therapy duration. Your MAC's LCD is the operative document for claim adjudication in your jurisdiction. If you don't know which MAC covers your region, look it up now — billing without that context is billing blind. |
| 2 | Audit active IVIg orders against the three patient subpopulation criteria. Run a report of all patients currently receiving IVIg for any of the five covered diagnoses. For each one, confirm the chart documents either failed conventional therapy, a contraindication to conventional therapy, or a rapidly progressive disease scenario with concurrent conventional treatment. Flag any chart where the documentation is thin. |
| 3 | Confirm biopsy results are in the record before submitting claims. This is a hard coverage requirement, not a documentation preference. "Biopsy-proven" means the pathology report is in the chart. If it's not, your claim will fail a medical necessity review. |
| 4 | Identify and remediate any maintenance therapy patterns. If a patient has been receiving IVIg infusions quarterly or on a rolling schedule without documented re-evaluation against the subpopulation criteria, that's a billing exposure. Work with your medical director to either document the ongoing clinical justification properly or transition the patient to a covered treatment model. Do this before March 7, 2026. |
| 5 | Update your prior authorization documentation templates. Because coverage is contingent on patient subpopulation criteria that MACs define locally, your prior auth requests need to speak directly to those criteria. Generic IVIg authorization requests that don't address failure of conventional therapy or contraindications will generate more denials. Revise your templates to match your MAC's language. |
| 6 | For rapidly progressive disease cases, document concurrent treatment explicitly. NCD 158 specifies that in rapidly progressive disease scenarios, IVIg is used alongside conventional treatment and only until conventional therapy takes effect. If your physician's orders and infusion records don't reflect that concurrent treatment structure, the claim is vulnerable. Make the documentation match the coverage rule. |
If your practice manages a high volume of IVIg infusions across multiple diagnoses or multiple MACs, talk to your compliance officer before March 7, 2026. The delegation of definitional authority to MACs means your exposure is jurisdiction-specific, and a compliance review of your current documentation practices against your MAC's LCD criteria is worth the time.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for IVIg Under NCD 158
NCD 158 does not list specific CPT or HCPCS billing codes. This is unusual for a drug and biologicals NCD and it has direct implications for your billing team.
The absence of code-level specificity in the NCD itself means your applicable billing codes — almost certainly HCPCS J-codes for IVIg products — are governed by your MAC's LCD and the specific IVIg product administered. HCPCS codes for IVIg products vary by formulation, concentration, and route of administration, and CMS assigns distinct J-codes to different IVIg products. The correct code is determined by what's actually administered, not by the diagnosis.
Check your MAC's LCD for the specific HCPCS codes it recognizes under NCD 158. If your MAC has an associated Billing and Coding Article, that article will list the covered ICD-10-CM diagnosis codes alongside the IVIg J-codes. Without your MAC's guidance, you're working from an incomplete picture.
Because we will not fabricate codes, we are not listing CPT, HCPCS, or ICD-10 codes here. This is one of those situations where citing invented codes would be actively harmful to your billing team. Go to your MAC's LCD directly.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.